Dishman successfully completes US FDA inspection

ALSO READ See latest News about Dishman Pharma See previous management interviews See what other Experts & Brokerages are saying about Dishman Pharma

Dishman  Pharmaceuticals  and  Chemicals  Limited  (Dishman) is pleased to announce  that  it  has  successfully  completed  US  FDA inspection for its facility  located  at Bavla, which is a 100% EOU, to manufacture Eprosartan Mesylate, an anti hyper-tension drug, to be supplied to Solvay Pharmaceuticals, BV, a fortune 500 company. 

Dishman is one of the two companies  in  the  world  with  whom  Solvay  hasentered into a long-term agreement for supply of newly developed molecule,whose patent is to expire in 2013.

With  this  event, Solvay will source its requirements for US markets from Dishman. Solvay  has  increased  the quantity of Eprosartan Mesylate to be supplied by Dishman by 50%.

Eprosartan  Mesylate  is  produced  from  three  Starting  Materials, whose process technology was developed by Dishman at its R & D, and Solvay having recognized  the  efforts  put in by Dishman in this development has entered into long-term Agreement to procure these Starting Materials to manufacture Eprosartan  Mesylate by the second supplier from whom Solvay is outsourcing its balance requirement of Eprosartan Mesylate.

 

Sourced From : Sobhagya Advertising Service